IL152417A0 - Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists - Google Patents

Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

Info

Publication number
IL152417A0
IL152417A0 IL15241701A IL15241701A IL152417A0 IL 152417 A0 IL152417 A0 IL 152417A0 IL 15241701 A IL15241701 A IL 15241701A IL 15241701 A IL15241701 A IL 15241701A IL 152417 A0 IL152417 A0 IL 152417A0
Authority
IL
Israel
Prior art keywords
alpha
receptor agonists
acetylcholine receptor
nicotinic acetylcholine
azabicyclic
Prior art date
Application number
IL15241701A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL152417A0 publication Critical patent/IL152417A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15241701A 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists IL152417A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds
PCT/EP2001/005008 WO2001085727A1 (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
IL152417A0 true IL152417A0 (en) 2003-05-29

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15241701A IL152417A0 (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

Country Status (29)

Country Link
US (1) US6780861B2 (de)
EP (1) EP1282620B1 (de)
JP (1) JP4898062B2 (de)
KR (1) KR20020093974A (de)
CN (1) CN1167703C (de)
AR (1) AR028073A1 (de)
AT (1) ATE263167T1 (de)
AU (2) AU2001262257B2 (de)
BR (1) BR0110521A (de)
CA (1) CA2407972C (de)
CZ (1) CZ20023622A3 (de)
DE (1) DE60102581T2 (de)
DK (1) DK1282620T3 (de)
ES (1) ES2218418T3 (de)
GB (1) GB0010955D0 (de)
HK (1) HK1054223B (de)
HU (1) HUP0301866A2 (de)
IL (1) IL152417A0 (de)
MX (1) MXPA02010892A (de)
NO (1) NO20025280L (de)
NZ (1) NZ522226A (de)
PE (1) PE20020221A1 (de)
PL (1) PL357435A1 (de)
PT (1) PT1282620E (de)
RU (1) RU2002131886A (de)
SK (1) SK15612002A3 (de)
TR (1) TR200401007T4 (de)
WO (1) WO2001085727A1 (de)
ZA (1) ZA200208969B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
WO2003040127A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04007936A (es) * 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
SK288115B6 (sk) * 2002-09-25 2013-09-03 Memory Pharmaceuticals Corporation Indazoles, pharmaceutical compositions comprising them and their use
DK1949901T3 (da) 2002-12-06 2014-05-19 The Feinstein Inst Medical Res Fremgangsmåde til bestemmelse af en cholinerg agonist selektiv for en alfa-7-nikotinsk receptor
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2005063767A2 (en) * 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
ATE437880T1 (de) 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
EP1742944B1 (de) * 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
US7632831B2 (en) * 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006069097A2 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2010059844A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
EP2959902A1 (de) * 2009-07-23 2015-12-30 Novartis AG Verwendung von azabicycloalkylderivaten zur behandlung oder vorbeugung von ataxie
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
CN102823159A (zh) * 2010-03-26 2012-12-12 康宁股份有限公司 低非线性长距离光传输系统
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
CN103260619A (zh) 2010-07-26 2013-08-21 英维沃医药有限公司 利用某些α-7烟酸受体激动剂与乙酰胆碱酯酶抑制剂的组合治疗认知障碍
CA2825142A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
MX365245B (es) * 2011-03-18 2019-05-28 Genzyme Corp Inhibidores de glucosilceramida sintasa.
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
CA2834467A1 (en) 2011-04-29 2012-11-01 Chiesi Farmaceutici S.P.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
EA034964B1 (ru) 2011-10-20 2020-04-13 Новартис Аг Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
KR102043309B1 (ko) 2012-12-11 2019-11-11 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커
JP2016508159A (ja) * 2013-01-15 2016-03-17 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
EP2945633B1 (de) 2013-01-15 2021-06-30 Novartis AG Verwendung von alpha-7-nikotinischen acetylcholinrezeptoragonisten
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
ZA957746B (en) * 1994-09-14 1996-07-25 Lundbeck & Co As H Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
ATE259807T1 (de) * 1996-06-05 2004-03-15 Lindner Wolfgang Prof Dr Auf cinchonan basierte chirale selektoren zur trennung von stereoisomeren
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
EP1217001B1 (de) * 1999-09-28 2005-12-07 Eisai Co., Ltd. Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
EP1381603A2 (de) * 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Mit aryl gruppen substituierte chinuklidine zur behandlung von krankheiten ( nikotin acetylcholin rezeptor liganden )
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
CN1167703C (zh) 2004-09-22
WO2001085727A1 (en) 2001-11-15
AU2001262257B2 (en) 2004-11-04
NO20025280D0 (no) 2002-11-04
RU2002131886A (ru) 2004-04-10
NO20025280L (no) 2002-11-04
CN1427840A (zh) 2003-07-02
HUP0301866A2 (hu) 2003-09-29
AR028073A1 (es) 2003-04-23
CZ20023622A3 (cs) 2003-02-12
CA2407972C (en) 2010-03-09
GB0010955D0 (en) 2000-06-28
NZ522226A (en) 2004-08-27
JP2003532731A (ja) 2003-11-05
US6780861B2 (en) 2004-08-24
US20030166654A1 (en) 2003-09-04
TR200401007T4 (tr) 2004-07-21
HK1054223B (zh) 2005-03-04
ES2218418T3 (es) 2004-11-16
DE60102581T2 (de) 2005-02-03
SK15612002A3 (sk) 2003-04-01
CA2407972A1 (en) 2001-11-15
PT1282620E (pt) 2004-07-30
ZA200208969B (en) 2003-10-07
MXPA02010892A (es) 2003-03-27
PE20020221A1 (es) 2002-04-23
EP1282620A1 (de) 2003-02-12
ATE263167T1 (de) 2004-04-15
PL357435A1 (en) 2004-07-26
DK1282620T3 (da) 2004-07-19
AU6225701A (en) 2001-11-20
DE60102581D1 (de) 2004-05-06
JP4898062B2 (ja) 2012-03-14
HK1054223A1 (en) 2003-11-21
EP1282620B1 (de) 2004-03-31
KR20020093974A (ko) 2002-12-16
BR0110521A (pt) 2003-04-08

Similar Documents

Publication Publication Date Title
IL152417A0 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
IL156499A0 (en) Quinuclidine carbamate derivatives and their use as m3 antagonists
ZA200200232B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
HUP0200332A2 (en) Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands pharmaceutical compositions comprising thereof and their use
AU2629800A (en) Nociceptin receptor orl-1 agonists for use in treating cough
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
AU2003212296A1 (en) Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
EP1176948A4 (de) Anti-nausea zusammensetzungen und methoden
PL370972A1 (en) 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
HUP0201426A2 (en) Fabric softening composition and its use
AU6031001A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PL378749A1 (pl) Azabicykliczne pochodne pirydyloksymetylowe i benzoizoksazolowe
ZA200104187B (en) 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists.
HRP970138A2 (en) Aminoalkyl- and acylaminoalkyl esters, process for their preparation and their use as bradykinin receptor antagonists
PL352432A1 (en) Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them
EP1037975A4 (de) Alpha-7 nikotinischer rezeptor
EG22491A (en) Rest-breaking composition and use thereof
SI1282620T1 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
IL148667A0 (en) Nicotinic acetylcholine receptor
ZA200101909B (en) Chemokine receptor antagonist and cyclosporin in combined therapy.
IL147128A0 (en) DITHIEPINO [6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS
HK1039332A1 (en) Piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907.
EP0928194A4 (de) Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors
ZA200202119B (en) Nicotinic acetylcholine receptor: alpha 10 subunit.
TW486994U (en) Upright and horizontal, dual-purpose milling machine